Evidence map›Paper›PMID 34626684›Full record

ArticleJournal of virological methods2022

Rapid and inexpensive purification of adenovirus vectors using an optimised aqueous two-phase technology.

Saqlain Suleman, Kuteiba Schrubaji, Chrysovalanto Filippou, Svetlana Ignatova, Peter Hewitson, Jonathan Huddleston, Rajvinder Karda, Simon N Waddington, Michael Themis

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virological methods, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Saqlain SulemanDivision of Biosciences, Department of Life Sciences, College of Health, Medicine & Life Sciences, Brunel University London, Uxbridge, Middlesex, UK.
Kuteiba SchrubajiDivision of Biosciences, Department of Life Sciences, College of Health, Medicine & Life Sciences, Brunel University London, Uxbridge, Middlesex, UK.
Chrysovalanto FilippouDivision of Biosciences, Department of Life Sciences, College of Health, Medicine & Life Sciences, Brunel University London, Uxbridge, Middlesex, UK.
Svetlana IgnatovaDepartment of Chemical Engineering, College of Engineering, Design & Physical Sciences, Brunel University London, Uxbridge, Middlesex, UB8 3PH, UK.
Peter HewitsonDepartment of Chemical Engineering, College of Engineering, Design & Physical Sciences, Brunel University London, Uxbridge, Middlesex, UB8 3PH, UK.
Jonathan HuddlestonDepartment of Chemical Engineering, College of Engineering, Design & Physical Sciences, Brunel University London, Uxbridge, Middlesex, UB8 3PH, UK.
Rajvinder KardaGene Transfer Technology, EGA Institute for Women's Health, University College London, London, WC1E 6HX, UK.
Simon N WaddingtonGene Transfer Technology, EGA Institute for Women's Health, University College London, London, WC1E 6HX, UK; MRC Antiviral Gene Therapy Research Unit, Faculty of Health Sciences, University of the Witswatersrand, Johannesburg, South Africa.
Michael ThemisDivision of Biosciences, Department of Life Sciences, College of Health, Medicine & Life Sciences, Brunel University London, Uxbridge, Middlesex, UK; Division of Ecology and Evolution, Department of Life Sciences, Imperial College London, London, SW7 2AZ, UK. Electronic address: michael.themis@brunel.ac.uk.
Brunel University of London · GBImperial College London · GBUniversity College London · GBUniversity of the Witwatersrand · ZA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adenoviruses (AdVs) are used as gene therapy vectors to treat human diseases and as vaccines against COVID-19. AdVs are produced by transfecting human embryonic kidney 239 (HEK293) or PER.C6 virus producer cells with AdV plasmid vectors or infecting these cells withcell lysates containing replication-defective AdV. Cell lysates can be purified further by caesium chloride or chromatographic protocols to research virus seed stocks (RVSS) for characterisation to high quality master virus seed stocks (MVSS) and working virus seed stocks (WVSS) before downstream production of pure, high titre AdV. Lysates are poorly infectious, block filtration columns and have limited storage capability. Aqueous two-phase systems (ATPS) are an alternative method for AdV purification that rapidly generates cleaner RVSS for characterisation to MVSS. After testing multiple ATPS formulations, an aqueous mixture of 20 % PEG 600 and 20 % (NH

Indexed as

COVID-19COVID-19 VaccinesAdenoviridaeGenetic VectorsHEK293 CellsHumansSARS-CoV-2TechnologyCOVID-19 VaccinesAdenovirus type 5Aqueous two-phase partitioning systemCaesium chlorideVaccineViral vector purification

Identifiers

PMID34626684
PMCPMC9757833
OpenAlexW3202632714

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.